2024

In the current climate of ongoing macroeconomic uncertainty, UBS analysts are advising investors to seriously consider implementing portfolio hedges. With the potential for market fluctuations and unforeseen challenges, having a well-diversified portfolio with hedges in place is crucial to mitigating risk. While gold has traditionally been viewed as a safe-haven asset, there are concerns regarding
0 Comments
Imax is gearing up for its largest “filmed for Imax” slate in 2025, with at least 14 titles currently in production using Imax film or Imax-certified digital cameras. This represents a significant increase from previous years, showcasing the growing interest from Hollywood and international filmmakers in creating content specifically for the Imax platform. Despite Imax
0 Comments
Asian stock markets have been on a rollercoaster ride recently, influenced by various economic data releases and geopolitical tensions. The recent soft consumer inflation readings in the US have led to speculation about interest rate cuts in 2024, creating a sense of optimism among investors. However, challenges from countries like China and Japan, coupled with
0 Comments
The U.S. stock index futures market showed relative stability on Wednesday, with minimal fluctuations in key indices such as the Dow Jones, S&P 500, and Nasdaq 100. Despite the calm trading environment, investors were eagerly awaiting the release of the monthly consumer price index (CPI) to gain insights into the Federal Reserve’s future monetary policy
0 Comments
In the first quarter of 2024, U.S. crypto exchange Coinbase reported a total of $56 billion in consumer trading volumes. This period coincided with bitcoin reaching record highs of close to $74,000. However, this figure pales in comparison to the $133.75 billion quarterly average seen during the 2021 rally, indicating a shift in retail trader
0 Comments
The Federal Reserve is currently under scrutiny as market experts debate the potential for rate cuts in the year 2024. Some believe that the Fed will implement two rate cuts, with the first one starting in September. However, if the inflation data does not show significant improvement by September, there might not be any rate
0 Comments
Regeneron Pharmaceuticals, Inc. stands as a prominent player in the biopharmaceutical industry, with a strong strategic focus on novel therapeutic areas. The company’s financial performance is robust, with a market capitalization of $103.43 billion, showcasing a substantial industry presence. Additionally, Regeneron’s earnings per share (EPS) have shown an upward trajectory, with projections indicating continued growth.
0 Comments